Acculaser gains FDA green light for cold laser:
This article was originally published in Clinica
Acculaser has gained clearance from the US FDA to market its cold laser technology as a non-surgical approach for treating pain associated with carpal tunnel syndrome. The condition, for which 200,000 surgical procedures are performed annually in the US, is characterised by chronic swelling of the tendons and nerves of the hand and wrist. The cold laser treatment, which can be given in the doctor's office by a trained therapist, avoids the risk of infection and other complications associated with surgery, and requires no recovery period, said the San Diego, California firm.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.